Profound Medical Corp.
NASDAQ:PROFMedical - Devices
+$0.27 today
- Market cap
- $253.09M
- Beta
- 0.52
- P/E (TTM)
- -6.3
- EPS (TTM)
- -$1.07
Volume 0.08M
Average 0.12M
PROF Common Stock
The par or stated value of issued common shares, plus paid-in capital where reported together.
Profound Medical Corp.NASDAQ: PROF
Common Stock · Q1 FY2026 · quarter ended Mar 2026
Common stock rises 15.5% from a year ago
Common stock stood at $325.23M at the end of Q1 FY2026, up 15.5% from a year earlier and down 26.7% from the prior quarter. Over 3 fiscal years it compounded at +29.2% a year.
Context
- Common stock amounted to 441.3% of total assets at the end of Q1 FY2026, down 21.4 pp from a year earlier.
- Common stock increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether common stock keeps rising in the next quarterly balance sheet after a +15.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Common Stock history
USD · from the balance sheet
- Latest · FY2025
- 443.54M USD
- Year-over-year change
- +57.5%
- 4-year CAGR
- +19.3%
| Period | Period end | Common Stock | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 443.54M | +57.5% |
| FY2024 | 2024-12-31 | 281.55M | +26.7% |
| FY2023 | 2023-12-31 | 222.21M | +8.0% |
| FY2022 | 2022-12-31 | 205.83M | -6.1% |
| FY2021 | 2021-12-31 | 219.28M | — |
Common Stock vs competitors
How PROF compares with its peers on the latest reported figures
- PROF's Mar 2026 common stock of $325.23M is the highest of the 11 companies compared; the peer median is $117.5K.
- Its year-over-year change of +15.5% is the 5th highest of 11, against a peer median of +7.6%.
- Common stock amounts to 441.3% of total assets for PROF, versus a peer median of 0.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $325.23M | +15.5% | +29.2% | 441.3% | |
| Mar 2026 | $1.07M | +0.8% | +1.4% | 0.6% | |
| Mar 2026 | $696K | +5.8% | +36.2% | 0.6% | |
| Mar 2026 | $366K | +1.1% | +0.3% | 0.5% | |
| Dec 2025 | $198K | +9.4% | +7.8% | 0.1% | |
| Mar 2026 | $121K | +2.5% | +2.6% | 0.2% | |
| Mar 2026 | $114K | +56.2% | -19.5% | 0.0% | |
| Mar 2026 | $25K | +25.0% | +22.2% | 0.0% | |
AVRAnteris Technologies Global Corp. | Mar 2026 | $10K | +150.0% | -97.1% | 0.0% |
| Mar 2026 | $5K | +66.7% | — | 0.0% | |
| Mar 2026 | $3K | -99.9% | +44.2% | 0.0% | |
| Peer median (excluding PROF) | $117.5K | +7.6% | +2.6% | 0.1% | |
Competitors are the stored peer set for PROF. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 67.06M | 46.52M | 26.21M | 54.91M | 81.8M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 1.41M | 6.34M | 7.29M | 7.05M | 9.86M |
| Inventory | 7.4M | 7.94M | 6.99M | 5.8M | 11.28M |
| Other Current Assets | 1.15M | 0 | 0 | 0 | 1.27M |
| Total Current Assets | 77.02M | 62.02M | 41.9M | 69.07M | 104.21M |
| Property, Plant & Equipment (Net) | 1.9M | 1.72M | 1.57M | 821.01K | 225K |
| Goodwill | 2.69M | 0 | 0 | 0 | 0 |
| Intangible Assets | 1.43M | 680K | 490K | 261K | 138K |
| Long-term Investments | 3.62M | 0 | 0 | 0 | 410.89K |
| Tax Assets | 0 | 0 | 0 | 87K | 0 |
| Other Non-current Assets | 0 | 0 | 0 | 0 | 87.96M |
| Total Non-current Assets | 9.64M | 2.4M | 2.06M | 1.17M | 88.73M |
| Total Assets | 86.66M | 64.42M | 43.96M | 70.23M | 192.94M |
| Account Payables | 3.18M | 2.03M | 865K | 1.32M | 2.14M |
| Short-term Debt | 249.66K | 523K | 2.1M | 1.74M | 291.73K |
| Tax Payables | 0 | 298K | 0 | 0 | 0 |
| Deferred Revenue | 476.35K | 471K | 721K | 419K | 0 |
| Other Current Liabilities | 247.66K | 621K | 1.42M | 1.03M | 5.83M |
| Total Current Liabilities | 4.15M | 4.19M | 6.37M | 6.57M | 8.32M |
| Long-term Debt | 0 | 6.65M | 5M | 2.92M | 6.16M |
| Deferred Tax Liabilities | 0 | 0 | 59K | 0 | 86.83M |
| Deferred Revenue (Non-current) | 873.82K | 764K | 728K | 49K | 531.42K |
| Other Non-current Liabilities | 0 | 0 | 73K | 71K | 108.2K |
| Total Non-current Liabilities | 2M | 8.23M | 6.36M | 3.25M | 93.63M |
| Total Liabilities | 6.15M | 12.42M | 12.73M | 9.81M | 101.95M |
| Common Stock | 219.28M | 205.83M | 222.21M | 281.55M | 443.54M |
| Retained Earnings | (160.48M) | (189.36M) | (217.35M) | (245.17M) | (394.1M) |
| Accumulated OCI | 4.74M | 16.84M | 5.57M | 2.74M | 6.88M |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 80.51M | 52M | 31.22M | 60.42M | 90.99M |
| Total Debt | 1.38M | 8.23M | 7.87M | 5.12M | 6.45M |
| Net Debt | (65.69M) | (38.29M) | (18.35M) | (49.79M) | (75.34M) |
Profound Medical Corp.
NASDAQ:PROF
Intrinsic Alpha fair value
Locked
Current Price
$6.91
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.